Citadel Advisors
CRDL

Citadel Advisors’s Cardiol Therapeutics CRDL Stock Holding History

Citadel Advisors’s Portfolio CRDL Stock Details CRDL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-1,700
Closed -$1.65K – 12870
2025
Q1 		$1.65K Sell
1,700
-2,100
-55% -$2.58K ﹤0.01% 14117
2024
Q4 		$4.86K Sell
3,800
-5,700
-60% -$9.61K ﹤0.01% 13898
2024
Q3 		$18.8K Buy
9,500
+2,100
+28% +$4.36K ﹤0.01% 12821
2024
Q2 		$14.9K Buy
+7,400
New +$15.7K ﹤0.01% 12855
2024
Q1 		– Sell
-1,000
Closed -$840 – 14659
2023
Q4 		$840 Buy
+1,000
New +$850 ﹤0.01% 13929
2023
Q1 		– Sell
-1,600
Closed -$816 – 14815
2022
Q4 		$816 Buy
+1,600
New +$975 ﹤0.01% 14578
2022
Q2 		– Sell
-30,500
Closed -$47K – 13009
2022
Q1 		$47K Sell
30,500
-40,200
-57% -$66.3K ﹤0.01% 12828
2021
Q4 		$131K Buy
+70,700
New +$195K ﹤0.01% 12434

Other funds holding CRDL

MI
MMCAP International Grand Cayman, Cayman Islands $1.18B AUM 50.44% 1-Year Est. Return
TC
Tejara Capital London, United Kingdom $243M AUM 9.84% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
IA
Integrity Alliance Urbandale, Iowa $3.2B AUM 23.28% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
PAM
PVG Asset Management Golden, Colorado $173M AUM 64.51% 1-Year Est. Return

Citadel Advisors's CRDL Position: Q2 2026 in Review

Citadel Advisors reduced its Cardiol Therapeutics (CRDL) stake by 2.9% in Q2 2026, selling an estimated $29.6K and leaving 796,529 shares worth $844K. The position accounts for ﹤0.01% of the portfolio, ranked #8633.

Citadel Advisors first reported a position in CRDL in Q4 2021 and has held it in 13 quarters since. The position peaked at $1.11M in Q1 2026. 52 funds tracked by Wall St. Rank hold CRDL as of Q2 2026.

  • Citadel Advisors held 796,529 shares of Cardiol Therapeutics worth $844K as of Q2 2026.
  • Citadel Advisors sold 23,375 Cardiol Therapeutics shares in Q2 2026, an estimated $29.6K.
  • Cardiol Therapeutics made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #8633 holding.
  • Citadel Advisors first reported a position in Cardiol Therapeutics in Q4 2021 and has held it in 13 quarters since.
  • Citadel Advisors's Cardiol Therapeutics position peaked at $1.11M in Q1 2026.
  • 52 funds tracked by Wall St. Rank held Cardiol Therapeutics as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.